Your browser doesn't support javascript.
loading
Pediatric opsoclonus-myoclonus-ataxia syndrome: Experience from a tertiary care university hospital.
Huddar, Akshata; Bindu, Parayil S; Nagappa, Madhu; Bharath, Rose D; Sinha, Sanjib; Mathuranath, Pavagada S; Taly, Arun B.
Afiliação
  • Huddar A; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.
  • Bindu PS; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.
  • Nagappa M; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.
  • Bharath RD; Department of Neuroimaging and Interventional Radiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.
  • Sinha S; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.
  • Mathuranath PS; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.
  • Taly AB; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.
Neurol India ; 66(5): 1332-1337, 2018.
Article em En | MEDLINE | ID: mdl-30232999
ABSTRACT

BACKGROUND:

Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare disorder; there is limited experience regarding its clinical course and therapeutic response. AIMS AND

OBJECTIVES:

To describe the clinical profile, investigations, and therapeutic outcome in pediatric OMAS. PATIENTS AND

METHODS:

Fourteen children (age 27.1 ± 7 months; male female = 12.3) suffering from OMAS seen over a period of 10 years (2006-2015) were included in the study. Their clinicodemographic profile, investigations, therapeutic outcome at follow-up, and relapses were reviewed.

RESULTS:

Ten children reported antecedent events (respiratory infection 7; gastrointestinal infection 1; vaccination 2). The most common referral diagnosis was acute cerebellitis (n = 8). Hypotonia (n = 9), abnormal behavior (n = 10), and neuroregression (n = 6) were also the frequent manifestations. Brain magnetic resonance imaging, cerebrospinal fluid, and urinary vanillylmandelic acid were normal in all the patients. Seven patients had an underlying tumor (abdomen 4; thorax 2; neck 1) detected by ultrasound (n = 2/14), computed tomography (CT) (n = 6/12), and fluorodeoxyglucose - positron emission tomography (n = 2/2). CT scan identified the tumor in 2 patients where metaiodobenzylguanidine scintigraphy was negative. All patients received steroids for 22.3 ± 20 months (3 months to 5 years). Eight required prolonged immunomodulation (>12 months). Complete remission after follow-up of 31.3 ± 19 months (7 months to 5 years) was noted in 5 patients, whereas the rest had persisting behavioral and cognitive abnormalities. Relapses were noted in 6 patients related to intercurrent infections (n = 5) and discontinuation of steroids (n = 1). The patients presented with isolated symptoms of the full-blown syndrome during their relapses.

CONCLUSION:

OMAS in children runs an indolent course requiring careful monitoring and long-term immunomodulation. An abnormal behavior is common and the outcome is variable.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Paraneoplásicas / Síndrome de Opsoclonia-Mioclonia Tipo de estudo: Prognostic_studies Limite: Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Neurol India Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Paraneoplásicas / Síndrome de Opsoclonia-Mioclonia Tipo de estudo: Prognostic_studies Limite: Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Neurol India Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Índia